Hikal Limited

BSE:524735 Stock Report

Market Cap: ₹46.7b

Hikal Past Earnings Performance

Past criteria checks 1/6

Hikal's earnings have been declining at an average annual rate of -7.8%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 4.5% per year. Hikal's return on equity is 6.1%, and it has net margins of 4%.

Key information

-7.8%

Earnings growth rate

-7.8%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate4.5%
Return on equity6.1%
Net Margin4.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hikal makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:524735 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2418,2147362,4640
30 Jun 2418,0346782,4390
31 Mar 2417,8466962,4860
31 Dec 2318,1587162,4340
30 Sep 2319,0848192,4530
30 Jun 2320,3239422,3890
31 Mar 2320,2307842,2520
31 Dec 2219,8016312,2300
30 Sep 2219,5448192,1280
30 Jun 2218,6471,0111,9850
31 Mar 2219,4271,6052,0820
31 Dec 2119,7281,9071,9580
30 Sep 2119,2161,8581,8380
30 Jun 2118,2451,6871,7040
31 Mar 2117,2041,3311,6810
31 Dec 2015,6701,0671,6580
30 Sep 2015,0779481,6320
30 Jun 2014,5697421,6030
31 Mar 2015,0738441,6040
31 Dec 1915,8589331,6720
30 Sep 1915,9349431,6460
30 Jun 1916,6721,1241,5950
31 Mar 1915,8961,0311,3880
31 Mar 1812,9617721,3000
31 Mar 1710,1396771,1890
31 Mar 169,2454121,1110
31 Mar 158,7054049190
31 Mar 148,2796391,1860

Quality Earnings: 524735 has high quality earnings.

Growing Profit Margin: 524735's current net profit margins (4%) are lower than last year (4.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 524735's earnings have declined by 7.8% per year over the past 5 years.

Accelerating Growth: 524735's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 524735 had negative earnings growth (-10.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20%).

Return on Equity

High ROE: 524735's Return on Equity (6.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 05:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hikal Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.
Kameswari V. S. ChavaliFirstCall Research
Siddhant KhandekarICICIdirect.com